Investing

Boston Scientific (BSX): Saving Itself Through Auctioning Off Pieces

Boston Scientific (BSX) did it shareholders a terrible disservice buy buying Guidant in a bidding war with Johnson & Johnson. It now has long-term debt of almost $8.3 billion. Troubles in its stent business have hurt earnings and the company lost money last quarter.

BSX shares which went from $13 five years ago to $44 in mid-2004, are back to $13. And, all of this is because management thought M&A would make the company bigger through cutting costs at an acquired company and relying on "synergy".

Well, it did not work, and now BSX has to auction off pieces of the company to save its skin and cover its debt service.

Boston Scientific has just sold its cardiac surgery and vascular surgery units off to Swedish company Getinge for $750 million in cash. These units went because, according to BSX, they were non-core assets.

When the going gets tough, all assets become "non-core".

Douglas A. McIntyre

It’s Your Money, Your Future—Own It (sponsor)

Are you ahead, or behind on retirement? For families with more than $500,000 saved for retirement, finding a financial advisor who puts your interest first can be the difference, and today it’s easier than ever. SmartAsset’s free tool matches you with up to three fiduciary financial advisors who serve your area in minutes. Each advisor has been carefully vetted and must act in your best interests. Start your search now.

If you’ve saved and built a substantial nest egg for you and your family, don’t delay; get started right here and help your retirement dreams become a retirement reality.

Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.

AI Portfolio

Discover Our Top AI Stocks

Our expert who first called NVIDIA in 2009 is predicting 2025 will see a historic AI breakthrough.

You can follow him investing $500,000 of his own money on our top AI stocks for free.